Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953615 · ClinicalTrials.gov registry record · Phase 2
Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00953615: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00953615 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953615, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.
Primary Outcome
The primary outcome was the change in serum liver biochemical parameter levels after 6 months of thalidomide when compared to baseline values. This was to be analyzed using the nonparametric Wilcoxon signed rank test of significance. This was based on the non-normal distribution of serum hepatic biochemical parameters among patients with PSC and the continuous nature of these variables.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Why NCT00953615 stopped before completion
NCT00953615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00953615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00953615 about?
NCT00953615 is a clinical study titled "Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)". The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.
What is the current status of trial NCT00953615?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2006-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00953615?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00953615?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00953615's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia